Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 466 to 480 of 684 results for kidney or kidneys or renal

  1. Cryotherapy for renal cancers (IPG207)

    This guidance has been updated and replaced by NICE HealthTech guidance 269 and HealthTech guidance 271.

  2. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  3. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

  4. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  5. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  6. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  7. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  8. OrganOx metra for liver transplant (MIB275)

    NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .

  9. Percutaneous cryotherapy for renal cancer (IPG402)

    Interventional procedures, IPG402 - Issued: July 2011 --> We have moved interventional procedures guidance 402 to become HealthTech guidance 269. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. Laparoscopic cryotherapy for renal cancer (IPG405)

    Interventional procedures, IPG405 - Issued: August 2011 --> We have moved interventional procedures guidance 405 to become HealthTech guidance 271. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

  12. Intravascular lithotripsy for calcified arteries in peripheral arterial disease (HTG707)

    Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.

  13. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (HTG685)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  14. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  15. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.